RAD-140

Overview

RAD-140 (testolone) is a selective androgen receptor modulator (SARM) that binds to androgen receptors with high affinity and selectivity. While not a peptide, it is commonly tracked in the peptide community due to overlapping use cases. It is studied for muscle wasting and breast cancer.

Mechanism of Action

RAD-140 selectively binds androgen receptors in muscle and bone tissue, producing anabolic effects (muscle growth, bone density) with reduced androgenic activity in prostate and sebaceous glands. It achieves tissue selectivity through differential co-regulator recruitment compared to testosterone.

Research Summary

Preclinical studies show significant lean mass gains and neuroprotective effects in animal models. A Phase 1 clinical trial in postmenopausal breast cancer patients demonstrated acceptable safety and preliminary anti-tumor activity. No FDA approval; regulatory agencies have issued warnings about SARMs in dietary supplements.

Dosing Information

Reported Side Effects

• Testosterone suppression
• Elevated liver enzymes
• Hair shedding
• Headache
• Aggression or mood changes

Research References

• RAD140, a nonsteroidal selective androgen receptor modulator, is neuroprotective in cell and animal models (2014)
• First-in-human Phase 1 dose escalation study of RAD140 in postmenopausal women with breast cancer (2023)
• Selective androgen receptor modulators (SARMs): a mini-review (2018)